Notably, data from TCGA has shown a co-enrichment of CDH1 and PIK3CA mutations in a significant proportion of LBC samples, supporting rationale for dual-pathway inhibition as a therapeutic strategy [3]. The gene discussed is CDH1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.